EUVIMEDEUVIMED entdecken
CrossrefInfokarte

Association of HDL cholesterol with incident age-related macular degeneration and mortality: using an illness-death model for interval-censored data to account for the competing risk of death

Blondy Kayembe-Mulumba, Petra P Larsen, Karen Leffondré, Pierre Joly, Jean-François Korobelnik, Cédric Schweitzer, Cécile Delcourt, Marie-Noëlle Delyfer

AJE Advances: Research in Epidemiology · 2025

DOI: 10.1093/ajeadv/uuaf015 ↗
AbstractBibliografische Angaben

Abstract

Abstract Elevated high-density lipoprotein cholesterol (HDL-C) has been regularly associated with age-related macular degeneration (AMD). However, this association could be due to longer life expectancy in subjects with high HDL-C. Thus, we assessed the association of HDL-C with incident AMD, using an illness-death model (IDM) for interval-censored data to account for death as a competing risk. The ALIENOR study included 963 participants aged 73 and older from Bordeaux, France. Plasma HDL-C was measured at baseline. AMD was assessed repeatedly using multimodal retinal imaging (2006-2020). The IDM estimated adjusted hazard ratios (aHR [95% confidence interval]) of incident AMD, and mortality in AMD-free and AMD-affected individuals. Analyzed samples included individuals at risk of intermediate (n = 472) and advanced (n = 690) AMD. HDL-C (1-standard deviation increase) was not significantly associated with the hazard of intermediate (aHR: 1.15 [0.97-1.37]) and advanced (aHR: 1.16 [0.90-1.49]) AMD onset. Additionally, in the intermediate AMD analysis, HDL-C was significantly associated with lower mortality in AMD-free (aHR: 0.74 [0.56-0.97]) and higher mortality in AMD-affected individuals (aHR: 1.55 [1.17-2.05]). Future research should leverage robust statistical methods, such as the IDM, to mitigate survival bias and enhance the accuracy of hazard ratios estimation to confirm our findings.

Wissen, das zu Ihrer Arbeit passt.

Vom kostenlosen Einstieg über die persönliche Recherche bis zur vollständigen Research Suite.

Tarife ansehen →

Sind alle Verlagsvolltexte enthalten?

Nein. Bibliografische Nachweise, Abstracts und Volltexte sind unterschiedliche Inhalte. Ob ein Volltext verfügbar ist, hängt von der Quelle, Open Access und Ihren vorhandenen Lizenzen ab. Ein EUVIMED-Tarif ersetzt keine zusätzlichen Verlagsrechte.

Tarife ansehen →